Vesicular Stomatitis Virus Encoding Ebola Virus Glycoprotein
The recombinant vesicular stomatitis virus (rVSV) vector encoding Ebola virus glycoprotein (rVSV-ZEBOV) is the active component of the Ervebo vaccine for prevention of Ebola virus disease caused by Zaire ebolavirus. The VSV backbone is replication-competent but highly attenuated, and the Ebola glycoprotein replaces the VSV glycoprotein, directing immune responses toward Ebola-specific antibody and T-cell immunity. It demonstrated high efficacy in ring vaccination studies during the West African Ebola outbreak.
Wirkmechanismus
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
The recombinant vesicular stomatitis virus (rVSV) vector encoding Ebola virus glycoprotein (rVSV-ZEBOV) is the active component of the Ervebo vaccine for prevention of Ebola virus disease caused by Zaire ebolavirus. The VSV backbone is replication-competent but highly attenuated, and the Ebola glycoprotein replaces the VSV glycoprotein, directing immune responses toward Ebola-specific antibody and T-cell immunity. It demonstrated high efficacy in ring vaccination studies during the West African Ebola outbreak.
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Yes, Vesicular Stomatitis Virus Encoding Ebola Virus Glycoprotein is an approved drug. It has reached clinical phase 4. It is classified as a Vaccine component.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL6068375. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="vesicular-stomatitis-virus-encoding-ebola-virus-glycoprotein"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/vesicular-stomatitis-virus-encoding-ebola-virus-glycoprotein/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/vesicular-stomatitis-virus-encoding-ebola-virus-glycoprotein/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/vesicular-stomatitis-virus-encoding-ebola-virus-glycoprotein/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="vesicular-stomatitis-virus-encoding-ebola-virus-glycoprotein"></drugfyi-drug>